Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
- Basilea Pharmaceutica Ltd has entered into an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553).
- Lisavanbulin is a potential therapy for glioblastoma, the most common type of primary brain cancer.
- The Glioblastoma Foundation will take over the development of lisavanbulin and continue the post-trial access program for patients.
- Basilea will receive an undisclosed initial purchase price and a fixed double-digit percentage of future commercial proceeds.
- Lisavanbulin has shown efficacy in phase 1 and 2 studies and has been granted Orphan Drug Designation by the FDA for malignant glioma.
- The Glioblastoma Foundation plans to initiate clinical trials of lisavanbulin in the US.
Read more
Macomics and IOR announce macrophage scientific collaboration in prostate cancer drug development
- Macomics Ltd and the Institute of Oncology Research (IOR) in Switzerland have entered a scientific collaboration.
- The collaboration focuses on myeloid-derived suppressor cells in prostate cancer mouse model systems.
- Macomics will work with Dr. Bianca Calì in Prof. Andrea Alimonti’s lab to explore new modes of action for macrophage-targeted therapies.
- The collaboration aims to test novel drug candidates using advanced in vivo prostate cancer models developed by the Alimonti lab.
- Macomics' ENIGMACâ„¢ macrophage drug discovery platform will be utilized to discover novel targets and de-risk clinical translation.
- The goal is to develop first-in-class medicines addressing diseases of high unmet medical need, particularly in prostate cancer.
Read more
Tubulis doses first patient in phase I/IIa trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma
- Tubulis has initiated its first Phase I/IIa trial (NAPISTAR 1-01, NCT06303505) for TUB-040.
- The trial targets patients with platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
- TUB-040 is an antibody-drug conjugate (ADC) targeting NaPi2b, an antigen overexpressed in ovarian cancer and lung adenocarcinoma.
- The study will be conducted in the US, UK, Spain, Belgium, and Germany.
- Phase Ia will focus on dose escalation and safety, while Phase IIa will focus on dose optimization and preliminary efficacy.
- The first patient has been dosed in the US following IND approval by the FDA.
Read more
iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
- iOnctura closed an EUR80 million Series B financing led by Syncona Limited.
- Funding will accelerate the development of roginolisib for uveal melanoma and other oncology indications.
- Roginolisib, an allosteric modulator of PI3Kδ, has shown promising efficacy in Phase Ib trials for uveal melanoma.
- Plans to commence trials in non-small cell lung cancer and primary myelofibrosis in late 2024.
- Cambritaxestat, an autotaxin inhibitor, is in Phase Ib trials for metastatic pancreatic cancer.
- Investors include the European Innovation Council Fund, M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.
Read more
Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
- NIH researchers developed a non-chemotherapy regimen called ViPOR for aggressive B-cell lymphoma.
- The five-drug combination includes venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide.
- In a clinical trial with 50 patients, 54% saw tumor reduction, and 38% achieved complete remission.
- At two years, 36% of patients were alive, and 34% were disease-free, especially in specific DLBCL subtypes.
- Side effects were generally mild to moderate, with only five patients discontinuing treatment early.
- A larger phase 2 study is planned to confirm ViPOR's efficacy in non-GCB DLBCL and double-hit GCB DLBCL.
Read more
